Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement> ?p ?o ?g. }
- Statement label "we recommend using alternate equivalent doses of steroids in the event that dexamethasone is unavailable." provenance.
- Statement label "we recommend using alternate equivalent doses of steroids in the event that dexamethasone is unavailable." provenance.
- Statement label "When exploring the effect of the rest of the therapies between groups (affected patients vs unaffected), We found no significant differences in bsDMARD proportions." provenance.
- Statement label "Dexamethasone and tocilizumab were considered in case of ARDS." provenance.
- Statement label "Dexamethasone and tocilizumab were considered in case of ARDS." provenance.
- Statement label "Dexamethasone and tocilizumab were considered in case of ARDS." provenance.
- Statement label "Dexamethasone and tocilizumab were considered in case of ARDS." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.
- Statement label "Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed." provenance.